Tejas Patil, MD
Hematology and Oncology
Locations
Practice Locations
UCHealth Lung Cancer Clinic - Anschutz Medical Campus
720-848-0300
University of Colorado Cancer Center
CU Anschutz Medical Campus
720-848-0300
Provider Expertise
Clinical Interest for Patients
My clinical and research interests include: (1) molecular diagnostics in lung cancer, (2) managing acquired resistance to targeted therapies (such as ALK, EGFR, ROS1 tyrosine kinase inhibitors), and (3) developing rational combinations of therapies based on evolutionary and molecular biology. I am also interested in novel clinical trials that address unmet needs among our patients with lung cancer.
Care Philosophy
I believe that there is no "one-size fits all" approach in medicine, especially with cancer therapy. I strive to use the best scientific principles available and tailor these to the individual needs and circumstances of each patient.
Specialties
- Hematology and Oncology ( 2020 )
- Internal Medicine ( 2016 )
Conditions & Treatments
-
Cancers
Cancer Medicine, Lung Cancer
Interests & Activities
Personal Interests
I am interested in targeted therapies and novel biomarkers. My true passion outside of medicine is classical piano performance. I also dabble with sketch comedy, film, and skiing on the side.
Education & Training
Medical Schools
MD, Keck School of Medicine of the University of Southern California (2013)
Undergraduate Schools
BA, University of Pennsylvania (Philadelphia, PA) (2007)
Internships
University of Colorado (2013)
Residency Program
University of Colorado (2016)
Fellowships
University of Colorado (2020)
Professional Memberships
Academic Thoracic Medical Oncology Consortium (ATOMIC), Voting Member
American Association of Cancer Research (AACR), Member
American Society of Clinical Oncology (ASCO), Member
Consortium for Intracranial Metastases Academic Research (CIMARA), Member
European Society for Clinical Oncology (ESMO), Member
Hoosier Cancer Research Network (HCRN), Voting Member
International Association for the Study of Lung Cancer (IASLC), Member
National Comprehensive Cancer Network (NCCN), Voting Member
Rocky Mountain Oncology Society (RMOS), President
SWOG Cancer Research Network, Lung Steering Committee
Research & Grants
Grants
Patterns of relapse in stage III NSCLC treated with curative intent and the utility of serum tumors markers in the surveillance setting (2019)
Personalized medicine models and linked electronic database to assess racial and socioeconomic disparities among patients with lung cancer in Colorado (2020)
Programmed death ligand 1 (PD-L1) expression as a biomarker for tyrosine kinase inhibitor (TKI) efficacy among patients with ALK-rearranged NSCLC (2022)
MET and EGFR as biomarkers for amivantamab in overcoming RET TKI resistance (2022)
Characterizing MET receptor tyrosine kinase adaptations of drug-tolerant persister cells in non-small cell lung cancer treated with tyrosine kinase inhibitors (2023)
Using spatial multi-omics to characterize receptor tyrosine kinase adaptations in drug-tolerant persister cells (2023)
Paul Calabresi Clinical Oncology Scholar (2024)
Cell cycling adaptations in drug-tolerant persister cells in non-small cell lung cancer treated with tyrosine kinase inhibitors (2024)
Research Interests for Patients
My research interests are in precision oncology, biomarker testing and development, targeted therapies, and characterizing acquired resistance to cancer therapies.
information for referring providers
Referral Contact Phone
Referring Patients Link
Clinical Interests for Referring Providers
My clinical and research interests include: (1) molecular diagnostics in lung cancer, (2) managing acquired resistance to targeted therapies (such as ALK, EGFR, ROS1 tyrosine kinase inhibitors), and (3) developing rational combinations of therapies based on evolutionary and molecular biology. I am also interested in novel clinical trials that address unmet needs among our patients with lung cancer.
Research Interest for Referring Providers
My translational research interests in lung cancer focus on three main themes: (1) leveraging molecular testing to identify prognostic and potentially predictive biomarkers to guide sequencing of anti-cancer therapies, (2) understanding the mechanisms of acquired resistance to targeted therapies, and (3) using evolutionary principles to develop rational anticancer therapy combinations to eradicate cancer persistence.
